

## Special Issue

# IECC2022: Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity

### Message from the Guest Editors

The focus of this Special Issue is the translation of basic science understanding the tumor microenvironment and its dysregulation in cancer to its therapeutic exploitation:

Tumor Heterogeneity and Chemoresistance  
Tumor Heterogeneity and Immune Evasion  
Clonal Evolution and Tumor Heterogeneity  
Technological Platforms for Tumor and TME  
Heterogeneity Studies  
Novel Computational Approaches in Tumor Analyses  
Proteomics and Metabolomics to Dissect Tumor Tissue  
Heterogeneity  
Targeting Tumor Microenvironment as Therapeutical  
Strategy to Hit Cancer: News from the Lab  
Pre-Clinical Models to Study Cancer Heterogeneity:  
Emerging Technologies  
Immunotherapy: Strategies to Unleash the Anti-Tumor  
Response

---

### Guest Editors

Prof. Dr. Samuel C. Mok  
Prof. Dr. Paola Cappello  
Dr. Sammy Ferri-Borgogno

---

### Deadline for manuscript submissions

closed (1 September 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/92842](https://mdpi.com/si/92842)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)